Abstract
Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The combination of a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist, dexamethasone, and a neurokinin-1 (NK-1) receptor antagonist has significantly improved the control of CINV. Palonosetronis a second generation 5-HT3 receptor antagonist. Netupitant is a new NK-1 receptor antagonist with a high binding affinity and a long half-life of 90 hours. NEPA is an oral fixed-dose combination of netupitant and palonosetron (300 mg of netupitant plus 0.50 mg of palonosetron). Phase II and phase III clinical trials have demonstrated that NEPA significantly improved the prevention of CINV compared to the use of palonosetron alone in patients receiving either highly or moderately emetogenic chemotherapy. Adverse events were similar for the NEPA and the palonosetron groups. NEPA (Akynzeo) has recently been approved by the Food and Drug Administration (FDA) to treat nausea and vomiting in patients undergoing cancer chemotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
